Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for selectively inhibiting T-cell rolling in a human ~~host~~ susceptible to symptoms of psoriasis, the method comprising the step ~~comprising~~ administering a compound that ~~selectively~~ interferes with ~~the CLA-E selectin, and LFA-1/ICAM, and VLA/VACAM interactions~~ at least one of the following interactions: a CLA and E-selectin interaction, a LFA-1/ICAM interaction or a VLA/VCAM interaction.

2. (Original) The method of claim 1 wherein said compound is an immunostimulant.

3. (Canceled).

4. Canceled

5. Canceled

6. Canceled

7. Canceled

8. Canceled

9. Canceled

10. Canceled.

11. Canceled.

12. Canceled

13. Canceled

14. Canceled

15. Canceled

16. Canceled

17. Canceled

18. Canceled

19. Canceled

20. Canceled.

21. (New) The method according to claim 1, wherein the compound includes an immunotherapeutic agent comprising an insoluble particulate antigen derived from isolated killed cells of amastigotes from at least one species of the *Leishmania* genus, the antigen comprising polypeptides having apparent molecular weights after total reduction and alkylation of about 73 kDa, about 80kDa and about 82 kDa.

22. (New) The method according to claim 21, wherein the isolated killed cells of amastigotes are derived from *Leishmania amazonensis*.

23. (New) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania venezuelensis*.

24 (New) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania brasiliensis*.

25. (New) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania chagasi*.

26. (New) The method according to claim 27, wherein the isolated killed cells of amastigotes are derived from *Leishmania amazonensis, Leishmania venezuelensis, Leishmania brasiliensis* and *Leishmania chagasi*.

27. (New) The method according to claim 21, wherein the 73 kDa polypeptide comprises the amino acid sequence set forth as:

(a) SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 6; or

(b) SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14.

28. (New) The method according to claim 21, wherein the 73 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 6.

29. (New) The method according to claim 21, wherein the 73 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14.

30. (New) The method according to claim 21, wherein the 80 kDa polypeptide comprises the amino acid sequence set forth as:

(a) SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 4; or

(b) SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10.

31. (New) The method according to claim 21, wherein the 80 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 4.

32. (New) The method according to claim 21, wherein the 80 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10.

33. (New) The method according to claim 21, wherein the 82 kDa polypeptide comprises the amino acid sequence set forth as:

(a) SEQ ID NO: 1 and SEQ ID NO: 2; or

(b) SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

34. (New) The method according to claim 21, wherein the 82 kDa polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 1 and SEQ ID NO: 2.

35. (New) The method according to claim 21, wherein the 82 kDA polypeptide of the antigen comprises the amino acid sequence set forth as SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

36. (New) The method according to claim 21, wherein the composition comprises

(a) at least one 73 kDa polypeptide comprising the amino acid sequence set forth as:

(i) SEQ ID NOS: 1, SEQ ID NO: 5, and SEQ ID NO: 6; or

(ii) SEQ ID NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14;

(b) at least one 80 kDa polypeptide comprising the amino acid sequence set forth as:

(i) SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4; or

(ii) SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10; and

(c) at least one 82 kDA polypeptide comprising the amino acid sequence set forth as:

(i) SEQ ID NO: 1 and SEQ ID NO: 2; or

(ii) SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.

37. (New) The method according to claim 21, wherein the immunotherapeutic agent comprises

(a) at least one 73 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NOS: 1, SEQ ID NO: 5, and SEQ ID NO: 6,

(b) at least one 80 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, and

(c) at least one 82 kDA polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 1 and SEQ ID NO: 2.

38. (New) The method according to claim 21, wherein the immunotherapeutic agent comprises

(a) at least one 73 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO:14;

(b) at least one 80 kDa polypeptide, comprising the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 10; and

(c) at least one 82 kDa polypeptide of the antigen comprising the amino acid sequence set forth as SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9.